Benign essential blepharospasm among residents of Olmsted county, Minesota, 1976 to 1995: An epidemiologic study

Ophthalmic Plastic and Reconstructive Surgery

Volumn 19, Issue 3, 2003, Pages 177-181

  Bradley, Elizabeth A ^a   Hodge, David O ^a   Bartley, George B ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN; ORPHENADRINE CITRATE;

ADULT; AGED; BIPOLAR DISORDER; BLEPHAROSPASM; CLINICAL FEATURE; COHORT ANALYSIS; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HEMIFACIAL SPASM; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MEIGE DISEASE; MYOKYMIA; PARKINSON DISEASE; PRIORITY JOURNAL; REMISSION; REVIEW; TREATMENT OUTCOME; UNITED STATES;

ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; BLEPHAROSPASM; BOTULINUM TOXINS; FEMALE; HUMANS; INCIDENCE; INJECTIONS; MALE; MIDDLE AGED; MINNESOTA; POISSON DISTRIBUTION; SEX DISTRIBUTION;

EID: 0038175120     PISSN: 07409303     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.IOP.0000065203.88182.CF     Document Type: Review

References (13)

1. Anderson RL, Patel BC, Holds JB, et al. Blepharospasm: past, present, and future. Ophthal Plast Reconstr Surg 1998;14:305-17.
2. Mauriello JA, Aljian J. Natural history of treatment of facial dyskinesias with botulinum toxin: a study of 50 consecutive patients over seven years. Br J Ophthalmol 1991;75:737-9.
3. Defazio G, Livrea P, De Salvia R, et al. Prevalence of primary blepharospasm in a community of Puglia region, Southern Italy. Neurology 2001;56:1579-81.
4. Nakashima K, Kusumi M, Inoue Y, et al. Prevalence of focal dystonias in the western area of Tottori Prefecture in Japan. Mov Disord 1995;10:440-3.
5. Nutt JG, Muenter MD, Melton LJ III, et al. Epidemiology of dystonia in Rochester, Minnesota. Adv Neurol 1988;50:361-5.
6. Bartley GB, Fatourechi V, Kadrmas EF, et al. The incidence of Graves' ophthalmopathy in Olmsted County, Minnesota. Am J Ophthalmol 1995;120:511-7.
7. Department of Health and Human Services. The international classification of diseases, 9th revision, clinical modification: ICD-9-CM. Washington, D.C.: Government Printing Office, 1998.
8. Jankovic J, Havins WE, Wilkins RB. Blinking and blepharospasm: mechanism, diagnosis, and management. JAMA 1982;248: 3160-4.
9. Bergstralh EJ, Offord KP, Chu CP, et al. Calculating incidence, prevalence, and morbidity rates for Olmsted County, Minnesota:an update. Technical Report Series. Division of Biostatistics. Rochester, Minnesota: 1992.
10. Grandas F, Elston J, Quinn N, et al. Blepharospasm: a review of 264 patients. J Neurol Neurosurg Psychiatry 1988;51:767-72.
11. Castelbuono A, Miller NR. Spontaneous remission in patients with essential blepharospasm and Meige syndrome. Am J Ophthalmol 1998;126:432-5.
12. Dutton JJ, Buckley EG. Botulinum toxin in the management of blepharospasm. Arch Neurol 1986;43:380-2.
13. Frueh BR, Felt DP, Wojno TH, et al. Treatment of blepharospasm with botulinum toxin: a preliminary report. Arch Ophthalmol 1984;102:1464-8.